A Canadian cancer trials group phase IB study of durvalumab (anti-PD-L1) plus tremelimumab (anti-CTLA-4) given concurrently or sequentially in patients with advanced, incurable solid malignancies

Conclusions Concurrent administration of durvalumab and tremelimumab over 1  h is safe with a comparable PK profile to sequential administration.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research